RESUMO
Parkinson's disease (PD) is aetiologically complex with both familial and sporadic forms. Familial PD results from rare, highly penetrant pathogenic mutations whereas multiple variants of low penetrance may contribute to the risk of sporadic PD. Common variants implicated in PD risk appear to explain only a minor proportion of the familial clustering observed in sporadic PD. It is therefore plausible that combinations of rare and/or common variants in genes already implicated in disease pathogenesis may help to explain the genetic basis of PD. We have developed a CustomSeq Affymetrix resequencing array to enable high-throughput sequencing of 13 genes (44 kb) implicated in the pathogenesis of PD. Using the array we sequenced 269 individuals, including 186 PD patients and 75 controls, achieving an overall call rate of 96.5% and 93.6%, for two respective versions of the array, and >99.9% accuracy for five samples sequenced by capillary sequencing in parallel. We identified modest associations with common variants in SNCA and LRRK2 and a trend suggestive of an overrepresentation of rare variants in cases compared to controls for several genes. We propose that this technology offers a robust and cost-effective alternative to targeted sequencing using traditional sequencing methods, and here we demonstrate the potential of this approach for either routine clinical investigation or for research studies aimed at understanding the genetic aetiology of PD.
Assuntos
Perfilação da Expressão Gênica , Predisposição Genética para Doença , Análise de Sequência com Séries de Oligonucleotídeos , Doença de Parkinson/genética , Polimorfismo de Nucleotídeo Único/genética , Adulto , Idoso , Feminino , Genótipo , Humanos , Serina-Treonina Proteína Quinase-2 com Repetições Ricas em Leucina , Masculino , Pessoa de Meia-Idade , Fenótipo , Proteínas Quinases/genética , Proteínas Serina-Treonina Quinases/genética , Reprodutibilidade dos Testes , Ubiquitina-Proteína Ligases/genética , alfa-Sinucleína/genéticaRESUMO
This study is an extension to previously published work that has linked variation in the human leukocyte antigen (HLA) class I region with susceptibility to multiple sclerosis (MS) in Australians from the Island State of Tasmania. Single nucleotide polymorphism (SNP) mapping was performed on an 865-kb candidate region (D6S1683-D6S265) in 166 Tasmanian MS families, and seven candidate genes [ubiquitin D (UBD), olfactory receptor 2H3 (OR2H3), gamma-aminobutyric acid B receptor 1 (GABBR1), myelin oligodendrocyte glycoprotein (MOG), HLA-F, HLA complex group 4 (HCG4) and HLA-G] were resequenced. SNPs tagging the extended MS susceptibility haplotype were genotyped in an independent sample of 356 Australian MS trios and SNPs in the MOG gene were significantly over-transmitted to MS cases. We identified significant effects on MS susceptibility of HLA-A*2 (OR: 0.51; P = 0.05) and A*3 (OR: 2.85; P = 0.005), and two coding polymorphisms in the MOG gene (V145I: P = 0.01, OR: 2.2; V142L: P = 0.04, OR: 0.45) after full conditioning on HLA-DRB1. We have therefore identified plausible candidates for the causal MS susceptibility allele, and although not conclusive at this stage, our data provide suggestive evidence for multiple class I MS susceptibility genes.
Assuntos
Mapeamento Cromossômico , Predisposição Genética para Doença , Antígenos HLA/genética , Antígenos de Histocompatibilidade Classe I/genética , Complexo Principal de Histocompatibilidade/genética , Esclerose Múltipla/genética , Polimorfismo de Nucleotídeo Único/genética , Análise de Sequência de DNA , Estudos de Casos e Controles , Feminino , Humanos , TasmâniaRESUMO
A system has been developed for measuring non-shunt cardiac output by the throughflow technique, using nitrous oxide in patients undergoing general anaesthesia. The throughflow measurement technique is a non-invasive method based on inert gas throughflow theory. In vitro validation of the measurement system was performed using a lung gas exchange simulator. The accuracy and precision of the throughflow measurement system was assessed by comparing measured and target values for five simulated values of non-shunt cardiac output, from 2.88 to 9.86 l min(-1). This showed an overall mean bias of -0.031 min(-1) (range -0.00 to -0.101 min(-1)), with a mean coefficient of variation of the difference of 1.39% (1.20-1.93%). These results indicate that the measurement system is suitable for monitoring the non-shunt cardiac output in patients undergoing general anaesthesia using nitrous oxide throughflow.